The first human clinical study on the pharmacokinetics and safety of PRM‐151, a recombinant human PTX2 protein, as a treatment for IPF, was a modest randomized, blinded, placebo‐controlled trial in 26 healthy volunteers between the ages of 18 and 53 years and 3 patients, 2 with familial interstitial pneumonia, and 1 with IPF, ages ranging between 29 and 72 years.122. This evidence concerns the gene APCS and idiopathic pulmonary fibrosis.